140 results on '"Gensler L"'
Search Results
2. POS0391 THE MSQUASH AS MEASUREMENT TOOL FOR DAILY PHYSICAL ACTIVITY: TRANSLATION AND CROSS-CULTURAL ADAPTATION INTO ENGLISH, FIELD-TESTING IN DIFFERENT RHEUMATIC DISEASES AND CLINICAL VALIDATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
3. POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
4. POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY
5. POS0512 SEX-RELATED DIFFERENCES IN TRIAL OUTCOMES IN AXIAL SPONDYLOARTHRITIS RANDOMIZED CLINICAL TRIALS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
6. POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
7. AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS
8. AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES
9. POS0501 GENDER AND AGE-OF-ONSET ARE ASSOCIATED WITH RADIOGRAPHIC PROGRESSION IN AXIAL SPONDYLOARTHRITIS
10. National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia
11. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
12. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis
13. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : analyse en sous-groupes avec sur le statut syndesmophytes et protéine C-réactive à l’inclusion
14. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : étude randomisée de phase 3b
15. Association of Sweet's Syndrome and Systemic Lupus Erythematosus.
16. AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
17. POS0683 AN EXPLORATORY ANALYSIS OF THE POTENTIAL DISCONNECT BETWEEN OBJECTIVE INFLAMMATORY RESPONSE AND CLINICAL RESPONSE FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS
18. OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY
19. AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
20. OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS
21. POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
22. POS0665 INCIDENCE RATE AND FACTORS ASSOCIATED WITH FRACTURES AMONG ADULTS WITH ANKYLOSING SPONDYLITIS IN THE UNITED STATES
23. POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
24. POS0299 EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL
25. OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
26. OP0154 COMORBIDITY CLUSTERS IN ANKYLOSING SPONDYLITIS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT: DATA FROM THE PSOAS COHORT
27. OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY
28. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES
29. POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
30. OP0023 A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG
31. POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
32. BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
33. LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
34. Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante : résultats à 3 ans d’une étude de phase IIb
35. Poursuite ou arrêt du traitement par l’ixékizumab chez des patients atteints de spondyloarthrite axiale et ayant atteint la rémission : résultats d’une étude de retrait randomisé, contrôlée versus placebo
36. Machine learning-based Berlin scoring of magnetic resonance images of the spine in patients with ankylosing spondylitis: Analysis of data from a phase 3 trial with Secukinumab
37. EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY.
38. POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
39. POS0923 INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1
40. OP0255 THE ROLE OF PELVIC MORPHOLOGY IN AXIAL SPONDYLOARTHRITIS
41. POS0904 FACTORS ASSOCIATED WITH SWITCHING FROM ONE ANTI-TNF AGENT TO ANOTHER ANTI-TNF, OR IL17 AGENT IN PATIENT WITH ANKYLOSING SPONDYLITIS
42. POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
43. POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE
44. Efficacité et tolérance à 52 semaines de l’ixékizumab dans la spondyloarthrite axiale radiographique chez des patients en réponse inadéquate ou intolérants aux anti-TNF
45. Le genre, l’âge ou la sous-population influencent-ils le maintien de la rémission clinique dans la spondyloarthrite axiale après une réduction de la dose de certolizumab pegol?
46. Le sécukinumab améliore les signes et symptômes de la spondyloarthrite axiale non radiographique : résultats d’une étude de phase III randomisée, contrôlée, stratifiée sur les signes objectifs d’inflammation à l’inclusion
47. Ixékizumab dans la spondyloarthrite axiale non-radiographique : résultats d’un essai de phase 3
48. Efficacité et sécurité d’emploi du bimekizumab dans la spondylarthrite ankylosante : résultats rapportés par les patients à 48 semaines dans une étude de phase IIb de détermination de la dose, randomisée, en double aveugle, contrôlée versus placebo
49. OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
50. AB1358-HPR DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: A PRIMARY UNMET EDUCATIONAL NEED FOR RHEUMATOLOGISTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.